Overview
Module 3: Risk Management corresponds to GVP Modules V, VIII, XV and XVI. In accordance with the GVP Module V on Risk Management System, Risk Management Plans (RMPs) should be submitted by companies to propose activities aiming to identify, characterise or minimise risks associated with medicinal products. Given the potential public health implications and costs of such interventions, RMPs should be based on robust data. Specific examples of data collection and analysis will be presented in this session. Besides, pharmaco-epidemiological studies, which are the fundamentals of “additional” Pharmacovigilance activities, are discussed. This session also presents recent developments regarding risk communication.
- Module 1: Post-Marketing
- Module 2: Regulatory Aspects in Pharmacovigilance
- Module 4: Signal Management
Program Committee
-
Wendy Huisman, PharmD Director
Vigifit, Netherlands -
Fakhredin Sayed Tabatabaei, MD, PhD Senior Assessor
MEB, Netherlands
Have an account?